The PI3K/mTOR Pathway Is Targeted by Rare Germline Variants in Patients with Both Melanoma and Renal Cell Carcinoma

Jean-Noël Hubert1, Voreak Suybeng2, Maxime Vallée1

  • 1Section of Genetics, International Agency for Research on Cancer (IARC-WHO), 69372 Lyon, France.

Cancers
|June 2, 2021
PubMed

Insights

This study reveals a genetic link between malignant melanoma and renal cell carcinoma (RCC), identifying shared rare variants in the PI3K/mTOR pathway. These findings suggest a potential genetic co-susceptibility for these cancers.

Area of Science:

  • Oncology
  • Genetics
  • Cancer Biology

Background:

  • Malignant melanoma and renal cell carcinoma (RCC) share biological properties like immune regulation and radioresistance, despite different origins.
  • An increased risk of one cancer is observed in patients with the other, suggesting a potential shared genetic basis.
  • Previous research has not fully explored the genetic co-susceptibility between malignant melanoma and RCC.

Purpose of the Study:

  • To clinically and genetically characterize patients with both malignant melanoma and RCC.
  • To identify germline genetic variants predisposing to both cancers.
  • To explore the role of rare variants in the PI3K/mTOR pathway in the co-occurrence of these cancers.

Main Methods:

  • Clinical and germline mutation testing in 125 patients with both malignant melanoma and RCC.
  • Whole-exome sequencing of 46 early-onset cases without identified germline variants.
  • Comparison of rare variants in 13 genes against 19,751 controls from The Cancer Genome Atlas (TCGA).

Main Results:

  • Pathogenic variants in known cancer predisposition genes (MITF, BAP1, CDKN2A, FLCN, PTEN) were found in 13.6% of cases.
  • Significant enrichment of rare, predicted deleterious variants in PI3K/mTOR pathway genes (PIK3CD, MTOR, etc.) and epigenetic modifiers (SETD2) in early-onset cases.
  • Association of germline variants with both melanoma and RCC confirmed in TCGA data, but not with lung cancer.

Conclusions:

  • Exome-wide case-control enrichment analysis can identify rare variants contributing to multiple primary cancers.
  • The co-occurrence of malignant melanoma and RCC is associated with germline variation in the PI3K/mTOR signaling pathway.
  • These findings have implications for early diagnosis and clinical management of patients with both cancers.

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.3K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.0K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.3K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
6.8K